Rivulet Media Inc (fka RIVU)

[Jleetx]

Could BMSN fall in this same category? My bet is YES!

"Biotechnology companies focused on developing drugs targeting orphan disease indications have recently been some of the best performers in Biotech. The success of companies with approved and marketed orphan drug products such as Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) has lead the new industry trend in niche disorders. According to EvaluatePharma's 2013 Orphan Drug Report, the industry shift towards the treatment of rare diseases is already in full swing as it is forecasted that one dollar out of every six spent on drugs in 2018 will go for a rare disease disorders. "